Metronomics in the neoadjuvant and adjuvant treatment of breast cancer

Research output: Contribution to journalShort survey

7 Citations (Scopus)

Abstract

The concept of metronomic chemotherapy (MC) has evolved from a descriptive preclinical phenomenon encompassing inhibition of angiogenesis to a clinically validated treatment concept involving multiple potential mechanisms of action. Clinicians are progressively more incline to consider MC as a component of mainstream medical oncology practice in advanced breast cancer. However, more recently MC has been tested even in the adjuvant/neoadjuvant setting, taking the opportunity to obtain tumor specimens and blood samples, in order to identify tumor-specific or patient-specific biomarkers for personalizing treatments. In addition, the antiangiogenic and pro-immune nature of metronomic chemotherapy made triple negative breast cancer (TNBC) a good candidate for exploring low-dose maintenance treatment in the adjuvant setting or in combination with immunomodulatory drugs. The potential development of MC in breast cancer pass through the research to identify biomarkers and individual tumor characteristics that can better address the use of this treatment strategy in the future. Finally, the subjective attitude of patients represents one of the major factors that influence the choice and acceptance of a therapeutic program. Personal preference and considerations about quality of life should guide the treatment choice eventually prioritizing the use of MC. Nevertheless, more robust data from randomized phase III trials are needed in the future, in order to make clinicians more confident in using metronomic strategies.

Original languageEnglish
Pages (from-to)259-266
Number of pages8
JournalCancer Letters
Volume400
DOIs
Publication statusPublished - Aug 1 2017

Fingerprint

Neoadjuvant Therapy
Breast Neoplasms
Drug Therapy
Therapeutics
Triple Negative Breast Neoplasms
Medical Oncology
Tumor Biomarkers
Action Potentials
Neoplasms
Biomarkers
Quality of Life
Research
Pharmaceutical Preparations

Keywords

  • Adjuvant treatment
  • Breast cancer
  • Immunomodulation
  • Metronomic chemotherapy
  • Neoadjuvant treatment
  • Triple negative

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Metronomics in the neoadjuvant and adjuvant treatment of breast cancer. / Munzone, Elisabetta; Colleoni, Marco.

In: Cancer Letters, Vol. 400, 01.08.2017, p. 259-266.

Research output: Contribution to journalShort survey

@article{04b616976e894b3fb5b598a711a5e2ee,
title = "Metronomics in the neoadjuvant and adjuvant treatment of breast cancer",
abstract = "The concept of metronomic chemotherapy (MC) has evolved from a descriptive preclinical phenomenon encompassing inhibition of angiogenesis to a clinically validated treatment concept involving multiple potential mechanisms of action. Clinicians are progressively more incline to consider MC as a component of mainstream medical oncology practice in advanced breast cancer. However, more recently MC has been tested even in the adjuvant/neoadjuvant setting, taking the opportunity to obtain tumor specimens and blood samples, in order to identify tumor-specific or patient-specific biomarkers for personalizing treatments. In addition, the antiangiogenic and pro-immune nature of metronomic chemotherapy made triple negative breast cancer (TNBC) a good candidate for exploring low-dose maintenance treatment in the adjuvant setting or in combination with immunomodulatory drugs. The potential development of MC in breast cancer pass through the research to identify biomarkers and individual tumor characteristics that can better address the use of this treatment strategy in the future. Finally, the subjective attitude of patients represents one of the major factors that influence the choice and acceptance of a therapeutic program. Personal preference and considerations about quality of life should guide the treatment choice eventually prioritizing the use of MC. Nevertheless, more robust data from randomized phase III trials are needed in the future, in order to make clinicians more confident in using metronomic strategies.",
keywords = "Adjuvant treatment, Breast cancer, Immunomodulation, Metronomic chemotherapy, Neoadjuvant treatment, Triple negative",
author = "Elisabetta Munzone and Marco Colleoni",
year = "2017",
month = "8",
day = "1",
doi = "10.1016/j.canlet.2016.12.041",
language = "English",
volume = "400",
pages = "259--266",
journal = "Cancer Letters",
issn = "0304-3835",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Metronomics in the neoadjuvant and adjuvant treatment of breast cancer

AU - Munzone, Elisabetta

AU - Colleoni, Marco

PY - 2017/8/1

Y1 - 2017/8/1

N2 - The concept of metronomic chemotherapy (MC) has evolved from a descriptive preclinical phenomenon encompassing inhibition of angiogenesis to a clinically validated treatment concept involving multiple potential mechanisms of action. Clinicians are progressively more incline to consider MC as a component of mainstream medical oncology practice in advanced breast cancer. However, more recently MC has been tested even in the adjuvant/neoadjuvant setting, taking the opportunity to obtain tumor specimens and blood samples, in order to identify tumor-specific or patient-specific biomarkers for personalizing treatments. In addition, the antiangiogenic and pro-immune nature of metronomic chemotherapy made triple negative breast cancer (TNBC) a good candidate for exploring low-dose maintenance treatment in the adjuvant setting or in combination with immunomodulatory drugs. The potential development of MC in breast cancer pass through the research to identify biomarkers and individual tumor characteristics that can better address the use of this treatment strategy in the future. Finally, the subjective attitude of patients represents one of the major factors that influence the choice and acceptance of a therapeutic program. Personal preference and considerations about quality of life should guide the treatment choice eventually prioritizing the use of MC. Nevertheless, more robust data from randomized phase III trials are needed in the future, in order to make clinicians more confident in using metronomic strategies.

AB - The concept of metronomic chemotherapy (MC) has evolved from a descriptive preclinical phenomenon encompassing inhibition of angiogenesis to a clinically validated treatment concept involving multiple potential mechanisms of action. Clinicians are progressively more incline to consider MC as a component of mainstream medical oncology practice in advanced breast cancer. However, more recently MC has been tested even in the adjuvant/neoadjuvant setting, taking the opportunity to obtain tumor specimens and blood samples, in order to identify tumor-specific or patient-specific biomarkers for personalizing treatments. In addition, the antiangiogenic and pro-immune nature of metronomic chemotherapy made triple negative breast cancer (TNBC) a good candidate for exploring low-dose maintenance treatment in the adjuvant setting or in combination with immunomodulatory drugs. The potential development of MC in breast cancer pass through the research to identify biomarkers and individual tumor characteristics that can better address the use of this treatment strategy in the future. Finally, the subjective attitude of patients represents one of the major factors that influence the choice and acceptance of a therapeutic program. Personal preference and considerations about quality of life should guide the treatment choice eventually prioritizing the use of MC. Nevertheless, more robust data from randomized phase III trials are needed in the future, in order to make clinicians more confident in using metronomic strategies.

KW - Adjuvant treatment

KW - Breast cancer

KW - Immunomodulation

KW - Metronomic chemotherapy

KW - Neoadjuvant treatment

KW - Triple negative

UR - http://www.scopus.com/inward/record.url?scp=85009822159&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85009822159&partnerID=8YFLogxK

U2 - 10.1016/j.canlet.2016.12.041

DO - 10.1016/j.canlet.2016.12.041

M3 - Short survey

C2 - 28093280

AN - SCOPUS:85009822159

VL - 400

SP - 259

EP - 266

JO - Cancer Letters

JF - Cancer Letters

SN - 0304-3835

ER -